SynthesisJournal of the American Heart Association2025
Adherence to Lipid-Lowering Therapies and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.
Synthesis in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Summary of the best evidence for non-pharmacological interventions for dyslipidemia in patients with coronary heart disease.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPersistently elevated low-density lipoprotein cholesterol is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Despite the availability of lipid-lowering therapy (LLT), most patients with ASCVD do not achieve guideline-recommended low-density lipoprotein cholesterol goals. Poor adherence to LLT is a key barrier to low-density lipoprotein cholesterol lowering and may be associated with adverse cardiovascular outcomes. We conducted a systematic review and meta-analysis to clarify the relationship between adherence to LLT and cardiovascular outcomes in patients with ASCVD.
methodsSystematic searches of PubMed, Embase, Scopus, and Cumulative Index to Nursing and Allied Health Literature were performed in March 2023 (updated September 2024). Observational studies in adults with clinical ASCVD reporting objective measures of adherence or persistence to LLT and cardiovascular outcomes, including death, cardiovascular death, and major adverse cardiovascular events, were included. Risk of bias was assessed using the Clinical Advances Through Research and Information Translation tool.
resultsOf 12 466 unique records identified, 39 met the inclusion criteria. Most studies only reported adherence to statins (33/39), and most measured adherence using proportion of days covered (25/39). Using an adherence threshold of ≥80%, adherence to LLT was shown to statistically significantly reduce risk of death (hazard ratio [HR], 0.56 [95% CI, 0.34-0.92];
conclusionsIn this systematic review and meta-analysis, adherence to LLT was associated with reduced risk of cardiovascular events in patients with clinical ASCVD. REGISTRATION: URL: https://www.crd.york.ac.uk/prospero/; identifier: CRD42023427146.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.